Global Tetanus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tetanus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
The global Tetanus Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Tetanus Vaccine include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Tetanus Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Tetanus Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Tetanus Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Tetanus Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
By Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
By Application
Adult
Pediatric
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Tetanus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Tetanus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tetanus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
The global Tetanus Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Tetanus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Tetanus Vaccine include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Tetanus Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Tetanus Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Tetanus Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Tetanus Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
By Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
By Application
Adult
Pediatric
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Tetanus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Tetanus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tetanus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices